Ligand's Partner Gloria Biosciences Receives Approval in China for Zimberelimab for the Treatment of Recurrent or Refractory Classical Hodgkin's LymphomaBusiness Wire • 08/30/21
Ligand Partner Travere Therapeutics Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study of Sparsentan in IgA NephropathyBusiness Wire • 08/16/21
Ligand Pharmaceuticals Incorporated (LGND) CEO John Higgins on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 07/30/21
Ligand Pharmaceuticals (LGND) Q2 Earnings and Revenues Top EstimatesZacks Investment Research • 07/29/21
Landing AI's LandingLens™ visual inspection software platform selected by Ligand Pharmaceuticals to further empower the OmniAb® and xPloration™ antibody discovery platformsPRNewsWire • 07/28/21
Ligand Partner Jazz Pharmaceuticals Launches RYLAZE™ (asparaginase erwinia chrysanthemi (recombinant)-rywn), Formerly JZP458Business Wire • 07/21/21
Ligand's Partner Merck Receives FDA Approval for VAXNEUVANCE™ for the Prevention of Invasive Pneumococcal Disease in Adults Caused by 15 SerotypesBusiness Wire • 07/19/21
Ligand Pharmaceuticals Appoints Dr. Jennifer Cochran to its Board of DirectorsBusiness Wire • 07/14/21
Ligand (LGND) Down 14% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 06/02/21
GenScript Biotech and Ligand Pharmaceuticals Enter into Global OmniAb® Licensing AgreementPRNewsWire • 06/02/21
Ligand Pharmaceuticals Incorporated (LGND) CEO John Higgins on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/04/21
Ligand Pharmaceuticals (LGND) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseZacks Investment Research • 04/26/21
Scalable Platform Business And Strong Pipeline Position Ligand For Long-Term GrowthSeeking Alpha • 04/15/21